

ONLINE APPENDIX

Additional Authors-

Alan Cass, M.D., Ph.D.,¹ Paul Glasziou, M.D., Ph.D.,² Stephen Harrap, M.D., Ph.D.,³ Liu Lisheng, M.D.,⁴ Guiseppe Mancina, M.D., Ph.D.,⁵ Avinesh Pillai, Ph.D.,¹ Neil Poulter, M.D.,⁶ Vlado Perkovic, M.D., Ph.D.,¹ Florence Travert, M.D.,⁷ on behalf of the ADVANCE Collaborative Group.

¹The George Institute For International Health, University of Sydney, Sydney, Australia; ²University of Oxford, Oxford, United Kingdom, and University of Queensland, Brisbane, Australia; ³University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia; ⁴Chinese Hypertension League Institute, Beijing, China; ⁵University of Milan-Biocca and San Gerardo Hospital, Milan, Italy; ⁶Imperial College and St Mary's Hospital, London, United Kingdom; ⁷Hôpital Bichat-Claude Bernard and Université Paris 7, Paris, France.

Conflicts of interest-

Prof Cass, reports receiving lecture fees from Servier; Prof Harrap, receiving lecture fees from Servier, Prof Mancina, receiving consulting and lecture fees Servier, Novartis, Bayer, Boehringer Ingelheim, Merck and Sanofi-Aventis; Prof Poulter, receiving consulting or lecture fees from Gilstead, Bristol-Myers-Squibb, Sanofi-Aventis, Daiichi, Merck, Preventicum, Pfizer and Novartis, and grant support from Servier, Pfizer, Mars and Menarini; Dr Perkovic, receiving lecture fees from Servier; Dr Travert, receiving lecture fees from Servier.

Supplementary Table - Concomitant therapy at baseline and end of 4.3 years follow up

	Registration visit				End of follow-up			
	Intensive + Per-ind (n=2783)	Standard + Per-ind (n=2788)	Intensive + Placebo (n=2786)	Standard + Placebo (n=2783)	Intensive + Per-ind (n=2480)	Standard + Per-ind (n=2428)	Intensive + Placebo (n=2443)	Standard + Placebo (n=2420)
Glucose Lowering Treatment								
Gliclazide modified-release, n (%)	207 (7.4)	226 (8.1)	215 (7.7)	217 (7.8)	2177 (89.5)	51 (2.2)	2141 (89.8)	48 (2.1)
Other sulfonylurea, n (%)	1799 (64.6)	1771 (63.6)	1779 (63.8)	1741 (62.6)	69 (2.8)	1398 (59.4)	69 (2.9)	1422 (60.7)
Metformin, n (%)	1704 (61.2)	1695 (60.8)	1692 (60.7)	1660 (59.6)	1781 (73.2)	1540 (65.4)	1787 (75.0)	1603 (68.5)
Thiazolidinediones, n (%)	95 (3.4)	109 (3.9)	106 (3.8)	97 (3.5)	442 (18.2)	269 (11.4)	423 (17.7)	286 (12.2)
Acarbose, n (%)	243 (8.7)	224 (8.0)	269 (9.6)	224 (8.0)	448 (18.4)	284 (12.1)	481 (20.2)	268 (11.4)
Glinides, n (%)	56 (2.0)	40 (1.4)	47 (1.7)	44 (1.6)	39 (1.6)	71 (3.0)	45 (1.9)	77 (3.3)
Any oral hypoglycemic drug, n (%)	2543 (91.4)	2539 (91.1)	2541 (91.1)	2506 (90)	2358 (97.0)	2080 (88.4)	2314 (97.1)	2108 (90.0)
Insulin, n (%)	44 (1.6)	36 (1.3)	38 (1.4)	41 (1.5)	1005 (41.3)	576 (24.5)	927 (38.9)	504 (21.5)
Blood Pressure Lowering Treatment								
Perindopril (open label), n (%)	238 (8.6)	252 (9.0)	211 (7.6)	238 (8.6)	1107 (45.6)	1021 (43.4)	1348 (56.6)	1243 (53.2)
Other angiotensin-converting enzyme inhibitor, n (%)	974 (35.0)	940 (33.7)	992 (35.6)	977 (35.1)	94 (3.9)	138 (5.9)	94 (3.9)	119 (5.1)
Angiotensin receptor blocker, n (%)	143 (5.1)	146 (5.2)	166 (6.0)	154 (5.5)	229 (9.4)	224 (9.5)	296 (12.4)	322 (13.8)
β-blockers, n (%)	661 (23.8)	683 (24.5)	691 (24.8)	694 (24.9)	760 (31.3)	732 (31.1)	846 (35.5)	825 (35.3)
Calcium antagonists, n (%)	837 (30.1)	832 (29.9)	865 (31.0)	893 (32.1)	763 (31.4)	768 (32.6)	1018 (42.8)	1022 (43.7)
Thiazides, n (%)	396 (14.2)	390 (14.0)	407 (14.6)	401 (14.4)	80 (3.3)	78 (3.3)	100 (4.2)	117 (5.0)
Other diuretics, n (%)	313 (11.2)	283 (10.2)	289 (10.4)	288 (10.4)	345 (14.2)	328 (13.9)	387 (16.3)	362 (15.5)
Other blood pressure lowering drugs, n (%)	356 (12.8)	344 (12.3)	322 (11.5)	361 (13.0)	252 (10.4)	211 (9.0)	309 (13)	329 (14.1)
Any blood pressure lowering drug, n (%)	2089 (75.1)	2077 (74.6)	2095 (75.1)	2105 (75.6)	1828 (75.2)	1806 (76.8)	2014 (84.6)	2010 (85.9)
Other Drugs								
Aspirin, n (%)	1210 (43.5)	1235 (44.3)	1249 (44.8)	1200 (43.1)	1380 (56.8)	1300 (55.2)	1309 (55)	1265 (54.1)
Other antiplatelets, n (%)	126 (4.5)	110 (3.9)	145 (5.2)	124 (4.5)	160 (6.6)	132 (5.6)	142 (6.0)	127 (5.4)
Statins, n (%)	756 (27.2)	782 (28.1)	798 (28.6)	810 (29.1)	1067 (43.9)	1059 (45.0)	1053 (44.2)	1079 (46.2)
Other lipid modifying drugs, n (%)	261 (9.4)	211 (7.6)	240 (8.6)	224 (8.0)	198 (8.1)	196 (8.3)	153 (6.4)	156 (6.7)